All In Biotech

Drug Trial Radar · NCT06182124

A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults

A PHASE 1/2, RANDOMIZED, DOUBLE-BLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,710 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,710

Actual

Start

Dec 20, 2023

Primary completion

May 12, 2026

Study completion May 12, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Dec 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety and immune effects of a pneumococcal vaccine in adults. This vaccine can possibly provide protection against further pneumococcal disease. This study will happen in 4 stages: Stage 1 is seeking participants who are between 18 years to 49 years of age. The participants will receive 1 of 2 pneumococcal vaccine candidates (different formulations) or 20vPnC (Prevnar 20) as a single shot given into the upper arm muscle. Stage 2 will begin after participants have completed Stage 1, and a pneumococcal vaccine candidate has been decided. Stage 2 is seeking participants who are adults 50 years of age and older. The participants will receive the chosen pneumococcal vaccine candidate from Stage 1 or 20vPnC (Prevnar 20). The vaccines will be given as a single shot into the upper arm muscle. Stage 3 is seeking participants who are adults 50 years of age and older. The participants will receive the chosen pneumococcal vaccine candidate from Stage 1 or a licensed pneumococcal comparator vaccine. The vaccines will be given as a single shot into the upper arm muscle. Stage 4 is seeking participants who are adults 50 years of age and older. The participants will receive either one of three pneumococcal vaccine candidates or one of two licensed pneumococcal comparator vaccines. The vaccines will be given as a single shot into the upper arm muscle. Participants will take part in this study for about 6 months for Stage 1, Stage 3, and Stage 4 and 12 months for Stage 2. During this time participants will have from 2 to 4 clinic visits and 1 phone visit. At these clinic visits, participants will be asked if any side effects were experienced. The participants will also have to give blood samples during these clinic visits.

Conditions

  • Pneumococcal Disease

Interventions

  • Multivalent Pneumococcal Vaccine - Formulation 1Biological

    Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stages 2, 3, and 4).

  • Multivalent Pneumococcal Vaccine - Formulation 2Biological

    Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stages 2, 3, and 4).

  • 20-valent pneumococcal conjugate vaccine (20vPnC)Biological

    20-valent pneumococcal conjugate vaccine (20vPnC)

  • Licensed pneumococcal comparator vaccineBiological

    A licensed pneumococcal comparator vaccine

  • Multivalent Pneumococcal Vaccine - Formulation 3Biological

    Multivalent pneumococcal conjugate vaccine

  • Multivalent Pneumococcal Vaccine - Formulation 4Biological

    Multivalent pneumococcal conjugate vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants reporting prespecified local reactions within 7 days after vaccinationTime frame: 7 days
  2. Percentage of participants reporting prespecified systemic events within 7 days after vaccinationTime frame: 7 days
  3. Percentage of participants reporting Adverse Events (AEs) within 1 month after vaccinationTime frame: 1 month
  4. Percentage of participants reporting Serious Adverse Events (SAEs) within 6 months after vaccinationTime frame: 6 months
  5. Phase 2 (Stage 2) Only: Percentage of participants reporting related Serious Adverse Events (SAEs) through 12 months after vaccinationTime frame: 12 months

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Alliance for Multispecialty Research, LLC

    Doral, Florida

  • Indago Research & Health Center, Inc

    Miami Lakes, Florida

  • Clinical Research Atlanta

    Stockbridge, Georgia

  • Optimal Research

    Peoria, Illinois

  • Alliance for Multispecialty Research, LLC

    New Orleans, Louisiana

  • Headlands Research - Detroit

    Southfield, Michigan

  • Rochester Clinical Research, LLC

    Rochester, New York

  • Accellacare - Wilmington

    Wilmington, North Carolina

  • AMR Clinical

    Knoxville, Tennessee

  • AMR Clinical

    Knoxville, Tennessee

  • Headlands Horizons LLC

    Brownsville, Texas

  • DM Clinical Research- Cyfair

    Houston, Texas

  • Clinical Trials of Texas, LLC dba Flourish Research

    San Antonio, Texas

  • IMA Clinical Research San Antonio

    San Antonio, Texas

  • Dynamed Clinical Research, LP d/b/a DM Clinical Research

    Sugar Land, Texas

  • Dynamed Clinical Research, LP d/b/a DM Clinical Research

    Tomball, Texas

  • J. Lewis Research, Inc. / Foothill Family Clinic

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.